pubmed.ncbi.nlm.nih.gov

May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)? - PubMed

  • ️Wed Jan 01 2020

Review

May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?

Raffaele Scarpa et al. J Transl Med. 2020.

Abstract

Background: In 1918 an unknown infectious agent spread around the world infecting over one-third of the general population and killing almost 50 million people. Many countries were at war, the First World War. Since Spain was a neutral country and Spanish press could report about the infection without censorship, this condition is commonly remembered as "Spanish influenza". This review examines several aspects during the 1918 influenza pandemic to bring out evidences which might be useful to imagine the possible magnitude of the present coronavirus disease 2019 (COVID-19).

Methods: In the first part of this review we will examine the origin of the SARS-Coronavirus-2 and 1918 Spanish Influenza Virus and the role played by host and environment in its diffusion. We will also include in our analysis an evaluation of different approaches utilized to restrain the spread of pandemic and to treat infected patients. In the second part, we will try to imagine the magnitude of the present COVID-19 pandemic and the possible measures able to restrain in the present environment its spread.

Results: Several factors characterize the outcome in a viral pandemic infection. They include the complete knowledge of the virus, the complete knowledge of the host and of the environment where the host lives and the pandemic develops.

Conclusion: By comparing the situation seen in 1918 with the current one, we are now in a more favourable position. The experience of the past teaches us that their success is linked to a rapid, constant and lasting application. Then, rather than coercion, awareness of the need to observe such prevention measures works better.

Keywords: Antiviral therapy; Biologics; COVID-19; Immune response; JAK-inhibitors; Monoclonal antibodies; Passive antibody administration; SARS-CoV-2; Spanish influenza; Vaccines.

PubMed Disclaimer

Conflict of interest statement

PAA has/had a consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD. RS, FC, LC, MGV, CT, ADP declare that they have no competing interests.

Similar articles

Cited by

References

    1. Short KR, Kedzierska K, van de Sandt CE. Back to the future: lessons learned from the 1918 influenza pandemic. Front Cell Infect Microbiol. 2018;8:343. doi: 10.3389/fcimb.2018.00343. - DOI - PMC - PubMed
    1. Burnet FM, Clark E. Influenza: a survey of the last fifty years. Melbourne: Macmillan Co.; 1942.
    1. Barry JM. The site of origin of the 1918 influenza pandemic and its public health implications. J Transl Med. 2004;2:3. doi: 10.1186/1479-5876-2-3. - DOI - PMC - PubMed
    1. Taubenberger JK, Reid AH, Krafft A, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 “Spanish” influenza virus. Science. 1997;275:1793–1796. doi: 10.1126/science.275.5307.1793. - DOI - PubMed
    1. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza polymerase genes. Nature. 2005;437:889–893. doi: 10.1038/nature04230. - DOI - PubMed

Publication types

MeSH terms

Substances